At PhinC Development, we help you identify, mitigate and overcome all the challenges you may face during your drug development process

NON-COMPARTMENTAL ANALYSIS (NCA)

When analyzing pharmacokinetic data, one generally employs either model fitting using nonlinear regression analysis or non-compartmental analysis techniques (NCA). The method one actually employs depends on what is required from the analysis. If the primary requirement is to determine the degree of exposure following administration of a drug (such as AUC), and perhaps the drug's associated pharmacokinetic parameters, such as clearance, elimination half-life, T (max), C (max), etc., then NCA is generally the preferred methodology to use in that it requires fewer assumptions than model-based approaches.

PhinC Development

PHINCS INTEGRATED & REPRODUCIBLE NON COMPARTMENTAL ANALYSIS PROCESS

1. Data Transfer Agreement (DTA) generation and validation
2. The NCA produces standard PK parameters to support regulatory decisions, such as FIH studies, special populations, bioequivalence and DDI.
3. The NCA may be customized for efficient early phase study design. Listings, tables and figures are always tailored to the specific purpose.
4. Quality Control (QC) integration in our process
5. We deliver state-of-the-art reporting and CDISC compliant PK data



At PhinC Development, we are dedicated to efficient drug development and contribute through the performance of fit for purpose analyses across the full product life-cycle. The Non-Compartmental Analysis (NCA) is a cost effective tool allowing for a rapid readout of pre-clinical and early clinical data. When performed within PhInc's Integrated and Reproducible Environment, the NCA can rapidly be extended to a pharmacometric model to leverage early clinical results.

CONTACT US TODAY TO GET A QUALIFICATION APPOINTMENT

Immeuble Le Classéa
36 rue Victor Basch
91300 Massy
France

+33 1 76 91 24 60

contact@phinc.fr

Follow us on social media:

PhinC Development